ArticlePloS one2015
Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 111 citations in OpenAlex.
- Bicyclononane-2,8-bis(trifluoromethyl)quinoline hybrids: synthesis, antiplasmodial and antitrypanosomal activity.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Evaluation of Human-Approved Active Pharmaceutical Ingredients Against Lactate Dehydrogenase from Theileria annulata.Acta parasitologica · 2026Article
- Investigation of In Vitro and In Vivo Anti-leishmanial Activity of Auranofin on Leishmania Infantum.Acta parasitologica · 2025Article
- Nifuroxazide and 4-Hydroxybenzhydrazone Derivatives as New Antiparasitic (Pharmaceutics · 2025Article
- PubChem BioAssays 1063: A Poorly Exploited Source of New Antileishmanial Compounds.Journal of parasitology research · 2025Article
- Compared Antileishmanial Activity of Clomiphene and Tamoxifen.Biomedicines · 2024Article
- Some Aspects and Convergence of Human and Veterinary Drug Repositioning.Molecules (Basel, Switzerland) · 2024Review
- A Review on Synthetic Thiazole Derivatives as an Antimalarial Agent.Current drug discovery technologies · 2024Review
- Evaluation of mono and combined nitrofurantoin therapy for toxoplasmosisPathogens and global health · 2023Article
- The Existing Drug Nifuroxazide as an Antischistosomal Agent:Microbiology spectrum · 2023Article
- Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis.Antimicrobial agents and chemotherapy · 2023Article
- Derivatives of Amaryllidaceae Alkaloid Ambelline as Selective Inhibitors of Hepatic Stage ofPharmaceutics · 2023Article
- Targeting trypanosomes: how chemogenomics and artificial intelligence can guide drug discovery.Biochemical Society transactions · 2023Review
- Impact of Laboratory-Adapted IntracellularMicroorganisms · 2023Article
- Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities.Frontiers in pharmacology · 2023Review
- Thio- and selenosemicarbazones as antiprotozoal agents againstJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Antileishmanial Activities of (Antimicrobial agents and chemotherapy · 2022Article
- An Overview on Target-Based Drug Design against Kinetoplastid Protozoan Infections: Human African Trypanosomiasis, Chagas Disease and Leishmaniases.Molecules (Basel, Switzerland) · 2021Review
- Preclinical Studies in Anti-Pharmaceuticals (Basel, Switzerland) · 2021Article
- In Vitro and In Vivo Trypanocidal Efficacy of Synthesized Nitrofurantoin Analogs.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neglected tropical diseases cause significant morbidity and mortality and are a source of poverty in endemic countries. Only a few drugs are available to treat diseases such as leishmaniasis, Chagas' disease, human African trypanosomiasis and malaria. Since drug development is lengthy and expensive, a drug repurposing strategy offers an attractive fast-track approach to speed up the process. A set of 100 registered drugs with drug repositioning potential for neglected diseases was assembled and tested in vitro against four protozoan parasites associated with the aforementioned diseases. Several drugs and drug classes showed in vitro activity in those screening assays. The results are critically reviewed and discussed in the perspective of a follow-up drug repositioning strategy where R&D has to be addressed with limited resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.